<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04792892</url>
  </required_header>
  <id_info>
    <org_study_id>ANCA II</org_study_id>
    <nct_id>NCT04792892</nct_id>
  </id_info>
  <brief_title>ANCA II - Quality of Life and Functional Outcome in Patients With Anal Cancer</brief_title>
  <acronym>ANCAII</acronym>
  <official_title>ANCA II - Quality of Life and Functional Outcome in Patients With Anal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sahlgrenska University Hospital, Sweden</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sahlgrenska University Hospital, Sweden</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Anal cancer is a rare disease, but the incidence is rising. About 200 patients will get this&#xD;
      type of cancer yearly in Sweden. Curative treatment includes chemotherapy and radiotherapy.&#xD;
      The prognosis is good, but some patients will have recurrent or persistent disease after&#xD;
      concluded chemo-radiotherapy and will then be offered salvage surgery. Some patients develop&#xD;
      distant metastases that can be treated with good results.&#xD;
&#xD;
      The aim of this study is to identify and describe functional outcome in patients diagnosed&#xD;
      with anal cancer. We will study patients from diagnosis, try to identify early toxicity to&#xD;
      treatment and then identify long-term morbidity.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 1, 2021</start_date>
  <completion_date type="Anticipated">April 1, 2034</completion_date>
  <primary_completion_date type="Anticipated">April 1, 2024</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>QoL</measure>
    <time_frame>3 months after diagnosis</time_frame>
    <description>Health related QoL at</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Urinary function</measure>
    <time_frame>3 months after diagnosis</time_frame>
    <description>Evaluate urinary dysfunction</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Bowel function</measure>
    <time_frame>3 months after diagnosis</time_frame>
    <description>Evaluate bowelfunction</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Sexual function</measure>
    <time_frame>3 months after diagnosis</time_frame>
    <description>Evaluate sexual function</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Toxicity related to treatment</measure>
    <time_frame>3 months after diagnosis</time_frame>
    <description>Number of patients with severe toxicity from the chemoradiotherapy</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>QoL</measure>
    <time_frame>12 months after diagnosis</time_frame>
    <description>QoL measured on a 7 point likert scale at 12 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urinary function</measure>
    <time_frame>12 months after diagnosis</time_frame>
    <description>Urinary dysfuntion measured as incontinence at 12 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bowel function</measure>
    <time_frame>12 months after diagnosis</time_frame>
    <description>Bowel dysfunction measured at 12 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sexual function</measure>
    <time_frame>12 months after diagnosis</time_frame>
    <description>Sexual dysfunction measured at 12 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>QoL</measure>
    <time_frame>3 years after diagnosis</time_frame>
    <description>QoL measured on a 7 point likert scale at 3 years</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urinary function</measure>
    <time_frame>3 years after diagnosis</time_frame>
    <description>Urinary function at 3 years</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bowel funcction</measure>
    <time_frame>3 years after diagnosis</time_frame>
    <description>Bowel dysfunction at 3 years</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sexual function</measure>
    <time_frame>3 years after diagnosis</time_frame>
    <description>Sexual dysfunction at 3 years</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">600</enrollment>
  <condition>Anal Cancer</condition>
  <arm_group>
    <arm_group_label>Patients with a new diagnosis of anal cancer</arm_group_label>
    <description>All patients identified at our national tumour board will be offered to participate</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Questionnaires</intervention_name>
    <description>Patients will be answering questionnaires at 0, 3, 12, 36, 60 and 120 months</description>
    <arm_group_label>Patients with a new diagnosis of anal cancer</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with newly diagnosed anal cancer&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age &gt; 18 years&#xD;
&#xD;
          -  Anal squamous carcinoma diagnosed within the last 2 months&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        -No informed consent&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Eva Angenete</last_name>
    <phone>0760514441</phone>
    <email>eva.angenete@vgregion.se</email>
  </overall_contact>
  <location>
    <facility>
      <name>Dept. of Surgery, Sahlgrenska University Hospital/Ostra</name>
      <address>
        <city>Gothenburg</city>
        <zip>SE 416 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eva Angenete, MD,PhD</last_name>
      <phone>+46313438410</phone>
      <email>eva.angenete@vgregion.se</email>
    </contact>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>March 10, 2021</study_first_submitted>
  <study_first_submitted_qc>March 10, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 11, 2021</study_first_posted>
  <last_update_submitted>October 16, 2021</last_update_submitted>
  <last_update_submitted_qc>October 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sahlgrenska University Hospital, Sweden</investigator_affiliation>
    <investigator_full_name>Eva Angenete</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anus Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

